facebook-script

Conor Daly, NTT IndyCar Series and NASCAR Xfinity Series Driver

An American professional racing driver who competes full-time while living with Type 1 Diabetes.

ConorDaly_LandingPageImage_2021

Conor Daly is a U.S.-born, professional racing driver who competes full-time while living with Type 1 Diabetes. Like many professional racing drivers, Daly started regularly competing in karting at the age of 10. Four years later, he found himself heading to the hospital having lost weight and possessing an insatiable thirst for water.

“I ended up not racing that day, but rather had tests run to learn what was going on with me,” Daly said. The answer came in the form of his Type 1 Diabetes diagnosis. “I knew that this was just another challenge life was presenting, and I wasn’t going to let it slow me down,” he said.

True to his conviction, less than a week later he was back to racing at the go-kart track and went on to take home the title at the 2006 World Karting Association Grand Nationals. Daly progressed to car racing in 2007, and has continued to thrive in the sport he loves. Over the past eight years, he has competed in over 100 NTT INDYCAR SERIES races, and has recently joined the NASCAR Xfinity Series.

Conor Daly is an Afrezza® user and a paid spokesperson for MannKind.

I was 14 when I got diagnosed with type one diabetes and, at the time, there was no one else in racing with diabetes…. and to be honest, I was racing five days out of the hospital after I was diagnosed.

Conor Daly

Racing is a demanding sport, and it takes a physical toll on your body.  With my hectic lifestyle, whether I’m on or off the track, I feel like I’m living life at 200+ miles an hour.

Conor Daly

Afrezza helps me lower my blood sugar fast and in combination with my CGM, it fits my active lifestyle.

Conor Daly

*Starts lowering blood sugar in ~12 minutes.

How Afrezza® Works

Fast In

Once inhaled, Afrezza® passes quickly through your lungs and enters your bloodstream in less than 1 minute. The ultra rapid-acting insulin allows Afrezza® to start lowering blood sugar in about 12 minutes.

FAST OUT

Afrezza® stops lowering blood glucose after 1.5 to 3 hours, depending on the dose.* This gives you the flexibility to take additional doses if needed, based on your blood glucose level after meals.

*For the 4-unit and 12-unit cartridges, respectively.

FITS YOUR LIFESTYLE

Afrezza®’s ultra rapid-action allows you to inhale your insulin right when food arrives, even unexpectedly, so you can be spontaneous but still in control, without the need for injections at mealtime.

Sign Up To Learn More!

Join Our List To Stay Updated With Helpful Information And Resources On Getting Started With Afrezza.







This field is for validation purposes and should be left unchanged.

*MannKind engages third party service providers to perform certain services on our behalf. Pursuant to our Privacy Policy, we may share your information with one or more of our service providers in order to help assess whether Afrezza® (insulin human) Inhalation Powder is appropriate for you. MannKind and its service provider may contact you in a number of ways, including phone, text and email. Your consent to being contacted is not required to purchase MannKind products or services, nor does it obligate you to purchase MannKind products or services. You may contact MannKind at any time to obtain additional information or to opt-out of receiving telephone calls, by calling 818-661-5000.

US-AFR-2160

Read more

What is AFREZZA?

Read more

Important Safety Information

What is the most important information I should know about AFREZZA? AFREZZA can cause serious side effects, including:

Sudden lung problems (bronchospasms). In a study, some AFREZZA-treated patients with asthma, whose asthma medication was temporarily withheld, experienced sudden lung problems. Do not use AFREZZA if you have long-term (chronic) lung problems such as asthma or chronic obstructive pulmonary disease (COPD). Before starting AFREZZA, your healthcare provider will give you a breathing test to check how your lungs are working.

 

Important Safety Information(cont’d)

Who should not use Afrezza®?

Do not use Afrezza® if you:

  • Have chronic lung problems such as asthma or COPD.
  • Are allergic to regular human insulin or any of the ingredients in Afrezza®.
  • Are having an episode of low blood sugar (hypoglycemia).

What should I tell my healthcare provider before using Afrezza®?

Before using Afrezza®, tell your healthcare provider about all your medical conditions, including if you:

  • Have lung problems such as asthma or COPD
  • Have or have had lung cancer
  • Are using any inhaled medications
  • Smoke or have recently stopped smoking
  • Have kidney or liver problems
  • Are pregnant, planning to become pregnant, or are breastfeeding. Afrezza® may harm your unborn or breastfeeding baby.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins or herbal supplements.

Before you start using Afrezza®, talk to your healthcare provider about low blood sugar and how to manage it.

What should I avoid while using Afrezza®?

While using Afrezza® do not:

  • Drive or operate heavy machinery, until you know how Afrezza® affects you.
  • Drink alcohol or use over-the-counter medicines that contain alcohol.
  • Smoke.

What are the possible side effects of Afrezza®?

Afrezza® may cause serious side effects that can lead to death, including:

See “What is the most important information I should know about Afrezza®?”

  • Low blood sugar (hypoglycemia). Signs and symptoms that may indicate low blood sugar include:
    • Dizziness or light-headedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability or mood change, hunger.
  • Decreased lung function. Your healthcare provider should check how your lungs are working before you start using AFREZZA, 6 months after you start using it, and yearly after that.
  • Lung cancer. In studies of Afrezza® in people with diabetes, lung cancer occurred in a few more people who were taking Afrezza® than in people who were taking other diabetes medications. There were too few cases to know if lung cancer was related to Afrezza®. If you have lung cancer, you and your healthcare provider should decide if you should use Afrezza®.
  • Diabetic ketoacidosis. Talk to your healthcare provider if you have an illness. Your Afrezza® dose or how often you check your blood sugar may need to be changed.
  • Severe allergic reaction (whole body reaction). Get medical help right away if you have any of these signs or symptoms of a severe allergic reaction:
    • A rash over your whole body, trouble breathing, a fast heartbeat, or sweating.
  • Low potassium in your blood (hypokalemia).
  • Heart failure. Taking certain diabetes pills called thiazolidinediones or “TZDs” with Afrezza® may cause heart failure in some people. This can happen even if you have never had heart failure or heart problems before. If you already have heart failure it may get worse while you take TZDs with Afrezza®. Your healthcare provider should monitor you closely while you are taking TZDs with Afrezza®. Tell your healthcare provider if you have any new or worse symptoms of heart failure including:
    • Shortness of breath, swelling of your ankles or feet, sudden weight gain.

Treatment with TZDs and Afrezza® may need to be changed or stopped by your healthcare provider if you have new or worse heart failure.

Get emergency medical help if you have:

• Trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, confusion.

The most common side effects of Afrezza® include:

  • Low blood sugar (hypoglycemia), cough, sore throat

These are not all the possible side effects of Afrezza®. Call your doctor for medical advice about side effects.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088 (1-800-332-1088).

Please See Full Prescribing Information, including BOXED WARNING, Medication Guide and Instructions for Use for AFREZZA.


AFREZZA, the Afrezza logo, AFREZZAASSIST, AFREZZAASSIST and logo, MANNKIND, and BLUHALE VIS are registered trademarks of MannKind Corporation. © 2024 MannKind Corporation.
This site is intended for use by U.S. residents only.